MétaCan
Menu
Back to cohort
Record W7093293508 · doi:10.71892/11143/1149

Traitement de l’adénocarcinome du pancréas avec le virus de la stomatite vésiculaire codant pour le transgène GM-CSF

2023· other· fr· W7093293508 on OpenAlexaboutno aff

Bibliographic record

VenueUSherbrooke-PROD · 2023
Typeother
Languagefr
FieldBiochemistry, Genetics and Molecular Biology
TopicVirus-based gene therapy research
Canadian institutionsnot available
Fundersnot available
KeywordsColonic diseaseVirusCancerImmune systemBreast cancer

Abstract

fetched live from OpenAlex

BACKGROUND Pancreatic cancer is the 8th most frequent cancer found in Canada for women and the 10th most frequent for men. Pancreatic ductal adenocarcinoma (PDAC) is the most frequent subtype of pancreatic cancer. Its survival rate is only at 8 % over 5 years, which makes it one of the most fatal cancers. Between 40 to 60 % of patients will receive their diagnosis at a late stage of their disease, which is inoperable. Surgery is presently the only option to cure patients. The standard of care for patients that are not operable is Folfirinox, a chemotherapeutic agent that is sometimes able to debulk the primary tumor to allow for tumor resection. However, the majority of patients cannot withstand chemotherapy for their PDAC due to severe cytotoxic side effects. In our laboratory, we are developing virotherapy as an alternative treatment option for PDAC patients. We are working with an oncolytic vesicular stomatitis virus armed with the transgene GM-CSF (VSV-GM-CSF) and we believe that it could kill cancer cells through cell lysis and induce an immune response to give pancreatic cancer patients a better chance of survival. AIMS Our goal was to compare the response in vitro and in vivo to different PDAC treatments such as Folfirinox alone, virus alone and a combination of the two. METHODS The human pancreatic cancer cell lines Mia-PaCa-2 and Panc01 as well as the mouse cell lines Panc02 and KPC were used for our experiment. We used 3 different viruses; one with the human transgene (VSVd51-hGM-CSF), one with the mouse transgene (VSVd51-mGM-CSF) and finally the parental virus with no transgene (VSVd51). We used a different virus for the mouse and the human because the GM-CSF protein is only 70% homologous between the two species. The functionality of our virus was confirmed using a cytotoxic assay, a replication assay and a ELISA to ensure the production of GM-CSF. The immunogenic cell death cause by the virus was analyzed by western blot to measure HMGB1 and HSP90, by flow cytometry for calreticuline and luminometric assay for ATP. For our in vivo model, we orthotopically implanted Panc02 directly into the mouse pancreas, followed by treatment with VSV-mGM-CSF, Folfirinox or the combination. RESULTS We can confirm that our virus armed with a transgene has the ability to kill, to reproduce itself and to produce the GM-CSF protein. In vitro data suggests that VSV-GM-CSF is better to induce cell death than chemotherapy and that a combination of the two therapies is also better than Folfirinox alone. In vivo, with no significant data, VSV-GM-CSF seems to be better than Folfirinox and the combination of the two for mice survival. This means that the virus could become an alternative treatment for PDAC patients in the future.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity, Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.438
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.263
Teacher spread0.250 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueUSherbrooke-PRODSame topicVirus-based gene therapy researchFrench-language works237,207